Key Principles from the Study
PROpel: In first-line mCRPC, the exploratory BRCA1/2-mutated subgroup had longer rPFS with olaparib + abiraterone versus abiraterone alone, both with prednisone/prednisolone (HR 0.24; 95% CI 0.12–0.45). PROfound: After progression on enzalutamide or abiraterone, the exploratory BRCA1/2-altered subgroup had longer rPFS with olaparib versus either ARPI (HR 0.22; 95% CI 0.15–0.32). Continue until progression or unacceptable toxicity; manage adverse events and adjust doses as needed. Individualize treatment based on prior ARPI and taxane exposure, comorbidities, and patient preferences.